<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title>Molecular Vision</journal-title><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">a51</article-id><article-id pub-id-type="publisher-id">2007MOLVIS</article-id><article-id pub-id-type="pmid">17417609</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Investigation of founder effects for the Thr377Met <italic>Myocilin</italic> mutation in glaucoma families from differing ethnic backgrounds</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hewitt</surname><given-names>Alex W.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Samples</surname><given-names>John R.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Allingham</surname><given-names>R. Rand</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>J&#x000e4;rvel&#x000e4;</surname><given-names>Irma</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kitsos</surname><given-names>George</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Krishnadas</surname><given-names>Subbaiah R.</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Richards</surname><given-names>Julia E.</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lichter</surname><given-names>Paul R.</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Petersen</surname><given-names>Michael B.</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sundaresan</surname><given-names>Periasamy</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wiggs</surname><given-names>Janey L.</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mackey</surname><given-names>David A.</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wirtz</surname><given-names>Mary K.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff id="aff1"><label>1</label>Department of Ophthalmology, Flinders University, Adelaide, Australia</aff><aff id="aff2"><label>2</label>Department of Ophthalmology, Casey Eye Institute-OHSU, Portland, OR</aff><aff id="aff3"><label>3</label>Department of Ophthalmology, Duke University Eye Center, Durham, NC</aff><aff id="aff4"><label>4</label>Department of Ophthalmology, University of Helsinki, Helsinki, Finland</aff><aff id="aff5"><label>5</label>Department of Ophthalmology, University of Ioannina, Ioannina, Greece</aff><aff id="aff6"><label>6</label>Department of Genetics, Aravind Medical Research Foundation, Madurai, India</aff><aff id="aff7"><label>7</label>Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI</aff><aff id="aff8"><label>8</label>Department of Genetics, Institute of Child Health, Athens, Greece</aff><aff id="aff9"><label>9</label>Department of Ophthalmology, Harvard Med School; Mass Eye &#x00026; Ear Infirmary, Boston, MA</aff><aff id="aff10"><label>10</label>Center for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Australia</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Associate Professor Mary Wirtz, Department of Ophthalmology, Casey Eye Institute, Oregon Health and Sciences University, 3375 SW Terwilliger Boulevard, Portland, OR, 97201-4197; Phone: (503) 494-4698; FAX: (503) 494-6875; email: <email xlink:href="wirtzm@ohsu.edu">wirtzm@ohsu.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>28</day><month>3</month><year>2007</year></pub-date><volume>13</volume><fpage>487</fpage><lpage>492</lpage><history><date date-type="received"><day>17</day><month>3</month><year>2007</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2007</year></date></history><permissions><copyright-year>2007</copyright-year><copyright-holder>Molecular Vision</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title>Purpose</title><p>The aim of this study was to determine if there is a common founder for the Thr377Met <italic>myocilin</italic> mutation in primary open angle glaucoma (POAG) families with various ethnic backgrounds.</p></sec><sec sec-type="methods"><title>Methods</title><p>Genomic DNA of 24 POAG-affected individuals from nine pedigrees with the Thr377Met mutation and 104 unaffected family members was genotyped with six microsatellite markers and four single nucleotide polymorphisms. The families were from Greece, India, Finland, the USA, and Australia. To assess the degree of linkage disequilibrium across <italic>MYOC</italic> in the general population we also investigated data generated from the HapMap consortium.</p></sec><sec><title>Results</title><p>Three distinct haplotypes associated with the Thr377Met <italic>myocilin</italic> mutation were identified. The families from the USA and Greece, as well as the three Australian families originating from Greece and the former Yugoslavian Republic of Macedonia had one common haplotype. Interestingly, however, HapMap data suggest that linkage disequilibrium across <italic>MYOC</italic> was not strong.</p></sec><sec><title>Conclusions</title><p>The Thr377Met myocilin mutation has arisen at least three separate times. Evidence for genetic founder effects in this prevalent age-related, yet heterogeneous, disease has important implications for future gene identification strategies.</p></sec></abstract><custom-meta-wrap><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Primary open angle glaucoma (POAG) is a complex heterogeneous disease and by the year 2020 is predicted to affect more than 50 million people worldwide [<xref ref-type="bibr" rid="r1">1</xref>]. Excavation of the optic disc with corresponding loss of visual field is the principal hallmark of POAG. Since its implication in the pathogenesis of POAG in 1997, numerous mutations in the <italic>myocilin</italic> (<italic>MYOC</italic>) gene have been identified and their specific phenotypes characterized [<xref ref-type="bibr" rid="r2">2</xref>,<xref ref-type="bibr" rid="r3">3</xref>]. The work recently performed by Shepard and colleagues has revealed that disease severity in <italic>MYOC</italic>-related POAG is influenced by exposure of a cryptic signaling site [<xref ref-type="bibr" rid="r4">4</xref>].</p><p>Worldwide, the Thr377Met <italic>MYOC</italic> mutation is one of the most commonly identified POAG-causing mutations and it has been previously identified in populations from five different continents. This specific mutation has been identified in four Australian-based families, two families residing in the United States of America, and one each from Greece, the former Yugoslavian Republic of Macedonia (FYROM), India, Finland, and Morocco [<xref ref-type="bibr" rid="r5">5</xref>-<xref ref-type="bibr" rid="r12">12</xref>]. The Thr377Met <italic>MYOC</italic> mutation is located within the COOH-terminal coding region and renders the protein insoluble [<xref ref-type="bibr" rid="r13">13</xref>]. Although this highly penetrant mutation appears to be sufficient to cause disease, evidence supporting gene-gene interaction in adult onset glaucoma has been described in a family harboring this variant [<xref ref-type="bibr" rid="r11">11</xref>]. Members of a Greek family who carried both the Thr377Met <italic>MYOC</italic> mutation and a haplotype associated with the GLC1C locus displayed greater disease severity than did those family members with only one disease variant [<xref ref-type="bibr" rid="r11">11</xref>].</p><p>In general, the Thr377Met mutation confers disease of intermediate severity, with patients typically being diagnosed in their fourth decade (weighted mean of age at diagnosis across described pedigrees=41.4 years). This is younger than the age at which patients with the Gln368Stop mutation are usually diagnosed, yet somewhat older than those carrying other <italic>MYOC</italic> mutations such as Pro370Leu, which is generally diagnosed around 15 years of age [<xref ref-type="bibr" rid="r5">5</xref>-<xref ref-type="bibr" rid="r12">12</xref>]. Following a similar pattern, patients with the Thr377Met mutation tend to have a maximum recorded intraocular pressure around 30 mmHg, lower than that described for mutations causing juvenile onset glaucoma (such as Pro370Leu), though generally higher than for the Gln368Stop mutation [<xref ref-type="bibr" rid="r7">7</xref>].</p><p>Inherited diseases with a relatively late onset may be more likely to have a common disease founder than those which manifest at a younger age. Evidence for a founding effect has previously been reported for the common Gln368Stop <italic>MYOC</italic> mutation; however, others, such as the Gly367Arg mutation, have arisen independently several times [<xref ref-type="bibr" rid="r14">14</xref>-<xref ref-type="bibr" rid="r16">16</xref>]. Small, local founder effects have also been identified for other less common mutations [<xref ref-type="bibr" rid="r9">9</xref>,<xref ref-type="bibr" rid="r14">14</xref>,<xref ref-type="bibr" rid="r17">17</xref>-<xref ref-type="bibr" rid="r19">19</xref>]. It is unclear whether a POAG variant causing intermediate disease severity would disseminate worldwide. Herein, we identified the haplotypes associated with the Thr377Met MYOC mutation to evaluate a possible founder effect in POAG families from various different ethnic backgrounds. To assess the degree of linkage disequilibrium across <italic>MYOC</italic> in the general population we also investigated data generated from the HapMap consortium.</p></sec><sec sec-type="methods"><title>Methods</title><p>Nine Thr377Met <italic>MYOC</italic> glaucoma pedigrees from the United States of America, Greece, Finland, India, and Australia were recruited. The four Australian families had emigrated from Great Britain, Greece, and Macedonia. Both families from the United States of America were of Greek ethnicity (<xref ref-type="table" rid="t1">Table 1</xref>). The Indian proband lived in a Sino-Tibetan linguistic region. This study adhered to the Declaration of Helsinki and ethical approval had previously been obtained by each research group's respective local Institutional Review Board, as previously reported [<xref ref-type="bibr" rid="r5">5</xref>-<xref ref-type="bibr" rid="r12">12</xref>].</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>Summary of phenotypic features of glaucomatous individuals carrying the Thr377Met <italic>MYOC</italic> mutation.</title></caption><table frame="hsides" rules="groups"><col width="75" span="1"/><col width="85" span="1"/><col width="74" span="1"/><col width="63" span="1"/><col width="64" span="1"/><col width="4" span="1"/><col width="68" span="1"/><col width="6" span="1"/><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><bold>Family designation</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Country of residence (Ancestral Ethnicity)</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>n ofPOAG orOHT individuals described</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Mean &#x000b1; SE age at diagnosis (years)</bold><hr/></td><td colspan="2" valign="top" align="center" rowspan="1"><bold>Mean &#x000b1; SE maximum recorded IOP (mmHg)</bold><hr/></td><td colspan="2" valign="top" align="center" rowspan="1"><bold>Previous Description of Pedigree</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Vicl<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Australia (British)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">19<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">39 &#x000b1;2.5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">29.9= 1.8<hr/></td><td colspan="2" valign="top" align="center" rowspan="1"> [<xref ref-type="bibr" rid="r5">5</xref>]<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Vicll8<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Australia (Greek)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">60<hr/></td><td colspan="2" valign="top" align="center" rowspan="1"> [<xref ref-type="bibr" rid="r5">5</xref>]<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Vic119<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Australia (Greek)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">42 &#x000b1;10<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">38&#x000b1;8<hr/></td><td colspan="2" valign="top" align="center" rowspan="1"> [<xref ref-type="bibr" rid="r5">5</xref>]<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Vic120<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Australia (Macedonian)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">47<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">30<hr/></td><td colspan="2" valign="top" align="center" rowspan="1"> [<xref ref-type="bibr" rid="r5">5</xref>]<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Epl<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Greece (Greek)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">51.3 &#x000b1;4.9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">32 &#x000b1;3.8<hr/></td><td colspan="2" valign="top" align="center" rowspan="1"> [<xref ref-type="bibr" rid="r11">11</xref>]<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">UMJG7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">USA (Greek)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">38 &#x000b1; 1.7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">44 &#x000b1;1.7<hr/></td><td colspan="2" valign="top" align="center" rowspan="1"> [<xref ref-type="bibr" rid="r7">7</xref>]<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">HMS7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">USA (Greek)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">42<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24<hr/></td><td colspan="2" valign="top" align="center" rowspan="1"> [<xref ref-type="bibr" rid="r6">6</xref>]<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Finl<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Finland (Finnish)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">34.3 &#x000b1; 8.8<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">33.2 &#x000b1;5.5<hr/></td><td colspan="2" valign="top" align="center" rowspan="1"> [<xref ref-type="bibr" rid="r10">10</xref>]<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Indl<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">India (Sino-Tibetan)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">52<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">44<hr/></td><td colspan="2" valign="top" align="center" rowspan="1"> [<xref ref-type="bibr" rid="r8">8</xref>]<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">Morocco (Berber)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">36</td><td valign="top" align="center" rowspan="1" colspan="1">70</td><td colspan="2" valign="top" align="center" rowspan="1">191</td></tr></tbody></table><table-wrap-foot><p>In the table, abbreviations are: n, number; SE, standard error; POAG, primary open angle glaucoma; OHT, ocular hypertension; IOP, intraocular pressure; USA, United States of America.</p></table-wrap-foot></table-wrap><p>Six microsatellite markers (D1S2851, MY3, My5, D1S1619, D1S2790, and D1S242) and four single nucleotide polymorphisms (rs3768570, rs235858, rs171000, and rs235873) located within a four Mb region surrounding the <italic>MYOC</italic> gene were genotyped in available subjects from each pedigree. Primer sequence and PCR conditions are available upon request. Haplotypes in each family were constructed by visual inspection of the genotype data, with no recombinations assumed between the markers. Genomic DNA was available from only one individual from the Indian cohort.</p><p>To estimate the probability of finding non-coincidental haplotypes segregating with the founded Thr377Met <italic>MYOC</italic> mutation, we determined the frequencies of the associated neighboring alleles in a sample of POAG patients originating from the same ethnic background. Thirty-three genealogically unrelated POAG patients of Greek ethnicity who, on direct sequencing, were found not to have the Thr377Met <italic>MYOC</italic> mutation, were recruited. The frequencies of the founded haplotype between the Greek Thr377Met <italic>MYOC</italic> mutation carrying patients and the Greek non-<italic>MYOC</italic> POAG patients was compared using Fisher's exact test (Intercooled Stata 7.0 for Windows; Stata Corporation, College Station, TX).</p><p>Allele frequencies and linkage disequilibrium across the chromosome region 1q24 was assessed using <ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org">HapMap</ext-link> data [<xref ref-type="bibr" rid="r20">20</xref>]. Phase I and II data were accessed from public release 21. This data release contains all processed data from the project including genotypes from the Affymetric 500 k genotyping array. HapMap comprises data of genotyped individuals from the Centre d'Etude du Polymorphisme Humain collection in Utah; the Yoruba in Ibadan, Nigeria; the Han Chinese in Beijing, China; and the Japanese in Tokyo, Japan [<xref ref-type="bibr" rid="r20">20</xref>]. Haplotype blocks were reviewed using Haploview 3.32 [<xref ref-type="bibr" rid="r21">21</xref>] and defined as having an upper confidence interval maximum for strong recombination of 0.9 [<xref ref-type="bibr" rid="r22">22</xref>]. Markers with a minor allele frequency below 0.05 were excluded [<xref ref-type="bibr" rid="r22">22</xref>].</p></sec><sec sec-type="results"><title>Results</title><p>Genotyping of the microsatellite markers revealed a shared haplotype in mutation carriers across six families from Greece, the United States of America, and Australia (<xref ref-type="table" rid="t2">Table 2</xref>). All of these families were known to be of Greek or Macedonian ethnicity and recombination was found to have occurred in a region telomeric to <italic>MYOC</italic> between D1S1619 and D1S2790.</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Ancestral disease haplotype shared by individuals carrying the Thr377Met <italic>MYOC</italic> mutation from different ethnic backgrounds.</title></caption><table frame="hsides" rules="groups"><col width="86" span="1"/><col width="91" span="1"/><col width="44" span="1"/><col width="68" span="1"/><col width="58" span="1"/><col width="52" span="1"/><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><bold>Marker</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Chromosome 1 location (Mb)</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Greek</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Australian (British)</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Indian</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Finnish</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">D1S2851<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">167.048<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">187<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">187<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">177 181<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">187<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">rs3768570<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">167.89<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">G/A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">A<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">rs235858<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">168.328<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">G/A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">A<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">rs171000<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">168.33<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">G/T<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">MY3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">168.336<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">176<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">174<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">174/ 178<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">178<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">rs235873<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">168.344<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">G/A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">A<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">My5 (NGA17)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">168.454<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">239<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">239<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">239<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">243<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">D1S1619<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">168.469<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">198<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">192<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">198/200<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">192<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">D1S2790<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">169.756<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">243<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">243 / 249<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">249<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">D1S242<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">171.104<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">215<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">221<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">217<hr/></td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">Number of contributing pedigrees:<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">Number of mutation carrying subjects haplotyped:</td><td valign="top" align="center" rowspan="1" colspan="1">26</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">4</td></tr></tbody></table></table-wrap><p>To investigate whether the haplotype observed in the Greek/FYROM Thr377Met <italic>MYOC</italic> families was inherited only by chance we genotyped a small cohort of POAG patients of Greek ethnicity who were known not to have the Thr377Met <italic>MYOC</italic> mutation. Although the precise phase could not be fully determined because of the limited availability of other family members, one Greek patient with POAG was found to have markers (between My3 and D1S1619) in common with the founded Greek Thr377Met <italic>MYOC</italic> mutation. However, even with the conservative assumption that this patient did have the founded MYOC haplotype, our data supports the rejection of the hypothesis that the Greek Thr377Met haplotype merely represents frequent alleles (p&#x0003c;0.0001).</p><p>The families from Finland and Great Britain were found to have differing haplotypes from each other and from those which originated from Greece or Macedonia. This suggests that the Thr377Met <italic>MYOC</italic> mutation has arisen at least three times worldwide. The Indian proband was found to have some markers in common both with the Finnish pedigree and the family which originated from Great Britain. However, given that only one case from this family could be ascertained, the haplotype segregating with the Thr377Met <italic>MYOC</italic> mutation could not be fully determined.</p><p>Reviewing the data generated by the HapMap consortium revealed that linkage disequilibrium across <italic>MYOC</italic>, particularly in the Utah residents, was not strong (<xref ref-type="fig" rid="f1">Figure 1</xref>). Larger linkage disequilibrium blocks over the genes neighboring <italic>MYOC</italic> (<italic>HbxAg transactivated protein 2</italic> and <italic>vesicle-associated membrane protein 4</italic>) were identified. In each population linkage disequilibrium was generally stronger across exons 2 and 3 compared to the 5' region of the <italic>MYOC</italic> gene.</p><fig id="f1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Haplotype blocks of the 320 kbp region containing the <italic>myocilin</italic> (<italic>MYOC</italic>) gene, in subjects from the Centre d'Etude du Polymorphisme Humain collection in Utah. The plotted D' statistic is orientated to the <italic>MYOC</italic> ideogram position and the strength of linkage disequilibrium is displayed in increasing shades of red for higher values. The relative gene locations are indicated by yellow bars.</p></caption><graphic xlink:href="mv-v13-487-f1"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Pre-symptomatic screening for glaucoma is an attractive prospect and although it may be currently uneconomical to introduce <italic>MYOC</italic> gene screening in a population-wide approach, targeted screening is warranted in selected populations. Our results imply that the Thr377Met <italic>MYOC</italic> mutation should be considered in glaucoma patients of Greek descent in particular.</p><p>A common haplotype was identified with the Thr377Met <italic>MYOC</italic> in six of the nine genealogically independent pedigrees studied. The northern boundary of Epirus, Greece, where the <italic>Ep1</italic> family in this report lives, forms the southern edge of the FYROM. Given this geographical proximity, we surmised that the Australian families from Greece and the FYROM have a common founder. However, the British, Finnish, and Indian families have a distinct haplotype from the Greek one, suggesting that the Thr377Met mutation has occurred de novo more than once (<xref ref-type="fig" rid="f2">Figure 2</xref>). Unfortunately refinement of the haplotype associated with this mutation in the Indian case was limited by the lack of genetically informative relatives. Nonetheless, we hypothesize that a Finnish-Indian connection would be at least 1,500 years old, from when the Finno-Ugric (Huns) people migrated from Central Asia. To investigate this inferred dissemination further it would be imperative to collect additional samples from the Indian Thr377Met <italic>MYOC</italic> family, as well as other unrelated Indian POAG cases. A limitation of our work is that the location of the centromeric and telomeric recombination in each pedigree was not identified. Such information would allow for the identification of the minimal common genomic distance between mutation carriers and, in turn, provide an estimation of the age at which the Thr377Met mutation occurred, yet is beyond the scope of this work [<xref ref-type="bibr" rid="r23">23</xref>,<xref ref-type="bibr" rid="r24">24</xref>].</p><fig id="f2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>The worldwide spread of the Thr377Met <italic>MYOC</italic> mutation. Stars indicate location of known origin, solid arrows indicate known migrations, and the dashed arrow indicates an inferred migration.</p></caption><graphic xlink:href="mv-v13-487-f2"/></fig><p>The population spread of human disease is significantly influenced by relative selection pressures and the existence of founder effects raises questions about whether such pressures are playing a role in <italic>MYOC</italic> allele frequencies. Our results, coupled with the late age at diagnosis (with the weighted mean across published pedigrees being 41.4 years), suggest that the Thr377Met <italic>MYOC</italic> mutation alone may not be significantly detrimental to reproduction. Although it is possible to arrive at a founder effect through non-selective processes such as genetic drift, it is plausible that this glaucoma-causing mutation may act as a protective factor against a separate ailment, thereby positively affecting biological fitness. Further insights may come from studies of Thr377Met allele frequencies in the Greek glaucoma populations. Evidence for genetic founder effects in this prevalent age-related, yet heterogeneous, disease has important implications for future gene identification strategies.</p><p>The haplotype structure across the comparatively small region surrounding <italic>MYOC</italic>, in conjunction with relatively small proportion of disease accounted for by mutations in <italic>MYOC</italic>, suggests that a high density SNP platform would be required for it to have been identified using a genome-wide association case-control approach. Nevertheless, genes with a different allelic architecture could be identified using such technology and, interestingly, a common disease haplotype has recently been associated with the common Y402H variant of <italic>Complement Factor H</italic> implicated in age-related macular degeneration [<xref ref-type="bibr" rid="r25">25</xref>]. Although confined conclusions based on the HapMap data must be approached with caution and the populations from which the data were generated should not be over-generalized, we found that linkage disequilibrium was marginally stronger across the regions with greater cross-species homology (particularly exon 3). Interestingly this supports other findings that on a genome-wide level sequence conservation appears not to be an important predictor of linkage disequilibrium [<xref ref-type="bibr" rid="r26">26</xref>].</p><p>In summary, the Thr377Met <italic>MYOC</italic> mutation has arisen at least three times in independent populations. Interestingly however, HapMap data suggest that linkage disequilibrium across <italic>MYOC</italic> is not strong. Evidence for genetic founder effects in this prevalent age-related, yet heterogeneous disease has important implications for future gene identification strategies.</p></sec></body><back><ack><title>Acknowledgements</title><p>This research was supported by NIH Grants EY11650, 5P30EY010572, EY015543, EY010886, AHAF, and an unrestricted grant from RPB to the Casey Eye Institute. AWH is the recipient of an Australian National Health and Medical Research Council postgraduate scholarship.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quigley</surname><given-names>HA</given-names></name><name><surname>Broman</surname><given-names>AT</given-names></name></person-group><article-title>The number of people with glaucoma worldwide in 2010 and 2020.</article-title><source>Br J Ophthalmol</source><year>2006</year><volume>90</volume><fpage>262</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16488940</pub-id></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Alward</surname><given-names>WL</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Polansky</surname><given-names>JR</given-names></name><name><surname>Sunden</surname><given-names>SL</given-names></name><name><surname>Nishimura</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>AF</given-names></name><name><surname>Nystuen</surname><given-names>A</given-names></name><name><surname>Nichols</surname><given-names>BE</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Kalenak</surname><given-names>JW</given-names></name><name><surname>Craven</surname><given-names>ER</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name></person-group><article-title>Identification of a gene that causes primary open angle glaucoma.</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>668</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9005853</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>AW</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name></person-group><article-title>Complex genetics of complex traits: the case of primary open-angle glaucoma.</article-title><source>Clin Experiment Ophthalmol</source><year>2006</year><volume>34</volume><fpage>472</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">16872346</pub-id></citation></ref><ref id="r4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shepard</surname><given-names>AR</given-names></name><name><surname>Jacobson</surname><given-names>N</given-names></name><name><surname>Millar</surname><given-names>JC</given-names></name><name><surname>Pang</surname><given-names>IH</given-names></name><name><surname>Steely</surname><given-names>HT</given-names></name><name><surname>Searby</surname><given-names>CC</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Clark</surname><given-names>AF</given-names></name></person-group><article-title>Glaucoma-causing myocilin mutants require the Peroxisomal Targeting Signal-1 Receptor (PTS1R) to elevate intraocular pressure.</article-title><source>Hum Mol Genet</source><year>2007</year>[Epub ahead of print]<pub-id pub-id-type="pmid">17317787</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Healey</surname><given-names>DL</given-names></name><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Coote</surname><given-names>MA</given-names></name><name><surname>Wong</surname><given-names>TL</given-names></name><name><surname>Wilkinson</surname><given-names>CH</given-names></name><name><surname>McCartney</surname><given-names>PJ</given-names></name><name><surname>Rait</surname><given-names>JL</given-names></name><name><surname>de Graaf</surname><given-names>AP</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name></person-group><article-title>Glaucoma phenotype in pedigrees with the myocilin Thr377Met mutation.</article-title><source>Arch Ophthalmol</source><year>2003</year><volume>121</volume><fpage>1172</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">12912696</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiggs</surname><given-names>JL</given-names></name><name><surname>Allingham</surname><given-names>RR</given-names></name><name><surname>Vollrath</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>KH</given-names></name><name><surname>De La Paz</surname><given-names>M</given-names></name><name><surname>Kern</surname><given-names>J</given-names></name><name><surname>Patterson</surname><given-names>K</given-names></name><name><surname>Babb</surname><given-names>VL</given-names></name><name><surname>Del Bono</surname><given-names>EA</given-names></name><name><surname>Broomer</surname><given-names>BW</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name></person-group><article-title>Prevalence of mutations in TIGR/Myocilin in patients with adult and juvenile primary open-angle glaucoma.</article-title><source>Am J Hum Genet</source><year>1998</year><volume>63</volume><fpage>1549</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">9792882</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>S</given-names></name><name><surname>Lichter</surname><given-names>PR</given-names></name><name><surname>Johnson</surname><given-names>AT</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Higashi</surname><given-names>M</given-names></name><name><surname>Gottfredsdottir</surname><given-names>M</given-names></name><name><surname>Othman</surname><given-names>M</given-names></name><name><surname>Moroi</surname><given-names>SE</given-names></name><name><surname>Rozsa</surname><given-names>FW</given-names></name><name><surname>Schertzer</surname><given-names>RM</given-names></name><name><surname>Clarke</surname><given-names>MS</given-names></name><name><surname>Schwartz</surname><given-names>AL</given-names></name><name><surname>Downs</surname><given-names>CA</given-names></name><name><surname>Vollrath</surname><given-names>D</given-names></name><name><surname>Richards</surname><given-names>JE</given-names></name></person-group><article-title>Age-dependent prevalence of mutations at the GLC1A locus in primary open-angle glaucoma.</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>130</volume><fpage>165</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">11004290</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanagavalli</surname><given-names>J</given-names></name><name><surname>Krishnadas</surname><given-names>SR</given-names></name><name><surname>Pandaranayaka</surname><given-names>E</given-names></name><name><surname>Krishnaswamy</surname><given-names>S</given-names></name><name><surname>Sundaresan</surname><given-names>P</given-names></name></person-group><article-title>Evaluation and understanding of myocilin mutations in Indian primary open angle glaucoma patients.</article-title><source>Mol Vis</source><year>2003</year><volume>9</volume><fpage>606</fpage><lpage>14</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v9/a74/">http://www.molvis.org/molvis/v9/a74/</ext-link><pub-id pub-id-type="pmid">14627955</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Idhajji</surname><given-names>A</given-names></name><name><surname>Driouiche</surname><given-names>S</given-names></name><name><surname>Hassani</surname><given-names>M</given-names></name><name><surname>Boukabboucha</surname><given-names>A</given-names></name><name><surname>Akhayat</surname><given-names>O</given-names></name><name><surname>Garchon</surname><given-names>H</given-names></name><name><surname>Belmouden</surname><given-names>A</given-names></name></person-group><article-title>Mutational analysis of the Myocilin gene in patients with primary open-angle glaucoma in Morocco.</article-title><source>Ophthalmic Genet</source><year>2003</year><volume>24</volume><fpage>153</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">12868033</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puska</surname><given-names>P</given-names></name><name><surname>Lemmela</surname><given-names>S</given-names></name><name><surname>Kristo</surname><given-names>P</given-names></name><name><surname>Sankila</surname><given-names>EM</given-names></name><name><surname>Jarvela</surname><given-names>I</given-names></name></person-group><article-title>Penetrance and phenotype of the Thr377Met Myocilin mutation in a large Finnish family with juvenile- and adult-onset primary open-angle glaucoma.</article-title><source>Ophthalmic Genet</source><year>2005</year><volume>26</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15823921</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>MB</given-names></name><name><surname>Kitsos</surname><given-names>G</given-names></name><name><surname>Samples</surname><given-names>JR</given-names></name><name><surname>Gaudette</surname><given-names>ND</given-names></name><name><surname>Economou-Petersen</surname><given-names>E</given-names></name><name><surname>Sykes</surname><given-names>R</given-names></name><name><surname>Rust</surname><given-names>K</given-names></name><name><surname>Grigoriadou</surname><given-names>M</given-names></name><name><surname>Aperis</surname><given-names>G</given-names></name><name><surname>Choi</surname><given-names>D</given-names></name><name><surname>Psilas</surname><given-names>K</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Kramer</surname><given-names>PL</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Wirtz</surname><given-names>MK</given-names></name></person-group><article-title>A large GLC1C Greek family with a myocilin T377M mutation: inheritance and phenotypic variability.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>620</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16431959</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allingham</surname><given-names>RR</given-names></name><name><surname>Wiggs</surname><given-names>JL</given-names></name><name><surname>De La Paz</surname><given-names>MA</given-names></name><name><surname>Vollrath</surname><given-names>D</given-names></name><name><surname>Tallett</surname><given-names>DA</given-names></name><name><surname>Broomer</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>KH</given-names></name><name><surname>Del Bono</surname><given-names>EA</given-names></name><name><surname>Kern</surname><given-names>J</given-names></name><name><surname>Patterson</surname><given-names>K</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name></person-group><article-title>Gln368STOP myocilin mutation in families with late-onset primary open-angle glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>1998</year><volume>39</volume><fpage>2288</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">9804137</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Vollrath</surname><given-names>D</given-names></name></person-group><article-title>A cellular assay distinguishes normal and mutant TIGR/myocilin protein.</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>2221</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10545602</pub-id></citation></ref><ref id="r14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faucher</surname><given-names>M</given-names></name><name><surname>Anctil</surname><given-names>JL</given-names></name><name><surname>Rodrigue</surname><given-names>MA</given-names></name><name><surname>Duchesne</surname><given-names>A</given-names></name><name><surname>Bergeron</surname><given-names>D</given-names></name><name><surname>Blondeau</surname><given-names>P</given-names></name><name><surname>Cote</surname><given-names>G</given-names></name><name><surname>Dubois</surname><given-names>S</given-names></name><name><surname>Bergeron</surname><given-names>J</given-names></name><name><surname>Arseneault</surname><given-names>R</given-names></name><name><surname>Morissette</surname><given-names>J</given-names></name><name><surname>Raymond</surname><given-names>V</given-names></name><collab>Quebec Glaucoma Network.</collab></person-group><article-title>Founder TIGR/myocilin mutations for glaucoma in the Quebec population.</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><fpage>2077</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">12189160</pub-id></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baird</surname><given-names>PN</given-names></name><name><surname>Richardson</surname><given-names>AJ</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Faucher</surname><given-names>M</given-names></name><name><surname>Raymond</surname><given-names>V</given-names></name></person-group><article-title>A common disease haplotype for the Q368STOP mutation of the myocilin gene in Australian and Canadian glaucoma families.</article-title><source>Am J Ophthalmol</source><year>2005</year><volume>140</volume><fpage>760</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">16226543</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>AW</given-names></name><name><surname>Bennett</surname><given-names>SL</given-names></name><name><surname>Dimasi</surname><given-names>DP</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name></person-group><article-title>A myocilin Gln368STOP homozygote does not exhibit a more severe glaucoma phenotype than heterozygous cases.</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>141</volume><fpage>402</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">16458712</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brezin</surname><given-names>AP</given-names></name><name><surname>Adam</surname><given-names>MF</given-names></name><name><surname>Belmouden</surname><given-names>A</given-names></name><name><surname>Lureau</surname><given-names>MA</given-names></name><name><surname>Chaventre</surname><given-names>A</given-names></name><name><surname>Copin</surname><given-names>B</given-names></name><name><surname>Gomez</surname><given-names>L</given-names></name><name><surname>De Dinechin</surname><given-names>SD</given-names></name><name><surname>Berkani</surname><given-names>M</given-names></name><name><surname>Valtot</surname><given-names>F</given-names></name><name><surname>Rouland</surname><given-names>JF</given-names></name><name><surname>Dascotte</surname><given-names>JC</given-names></name><name><surname>Bach</surname><given-names>JF</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name></person-group><article-title>Founder effect in GLC1A-linked familial open-angle glaucoma in Northern France.</article-title><source>Am J Med Genet</source><year>1998</year><volume>76</volume><fpage>438</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">9556305</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Angius</surname><given-names>A</given-names></name><name><surname>De Gioia</surname><given-names>E</given-names></name><name><surname>Loi</surname><given-names>A</given-names></name><name><surname>Fossarello</surname><given-names>M</given-names></name><name><surname>Sole</surname><given-names>G</given-names></name><name><surname>Orzalesi</surname><given-names>N</given-names></name><name><surname>Grignolo</surname><given-names>F</given-names></name><name><surname>Cao</surname><given-names>A</given-names></name><name><surname>Pirastu</surname><given-names>M</given-names></name></person-group><article-title>A novel mutation in the GLC1A gene causes juvenile open-angle glaucoma in 4 families from the Italian region of Puglia.</article-title><source>Arch Ophthalmol</source><year>1998</year><volume>116</volume><fpage>793</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9639450</pub-id></citation></ref><ref id="r19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>AW</given-names></name><name><surname>Bennett</surname><given-names>SL</given-names></name><name><surname>Richards</surname><given-names>JE</given-names></name><name><surname>Dimasi</surname><given-names>DP</given-names></name><name><surname>Booth</surname><given-names>AP</given-names></name><name><surname>Inglehearn</surname><given-names>C</given-names></name><name><surname>Anwar</surname><given-names>R</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Heon</surname><given-names>E</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name></person-group><article-title>Myocilin Gly252Arg mutation and glaucoma of intermediate severity in Caucasian individuals.</article-title><source>Arch Ophthalmol</source><year>2007</year><volume>125</volume><fpage>98</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">17210859</pub-id></citation></ref><ref id="r20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><collab>The International HapMap Consortium</collab></person-group><article-title>The International HapMap Project.</article-title><source>Nature</source><year>2003</year><volume>426</volume><fpage>789</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">14685227</pub-id></citation></ref><ref id="r21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15297300</pub-id></citation></ref><ref id="r22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Schaffner</surname><given-names>SF</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Moore</surname><given-names>JM</given-names></name><name><surname>Roy</surname><given-names>J</given-names></name><name><surname>Blumenstiel</surname><given-names>B</given-names></name><name><surname>Higgins</surname><given-names>J</given-names></name><name><surname>DeFelice</surname><given-names>M</given-names></name><name><surname>Lochner</surname><given-names>A</given-names></name><name><surname>Faggart</surname><given-names>M</given-names></name><name><surname>Liu-Cordero</surname><given-names>SN</given-names></name><name><surname>Rotimi</surname><given-names>C</given-names></name><name><surname>Adeyemo</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>R</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name></person-group><article-title>The structure of haplotype blocks in the human genome.</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>2225</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12029063</pub-id></citation></ref><ref id="r23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slatkin</surname><given-names>M</given-names></name></person-group><article-title>Allele age and a test for selection on rare alleles.</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>2000</year><volume>355</volume><fpage>1663</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11127913</pub-id></citation></ref><ref id="r24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Genin</surname><given-names>E</given-names></name><name><surname>Tullio-Pelet</surname><given-names>A</given-names></name><name><surname>Begeot</surname><given-names>F</given-names></name><name><surname>Lyonnet</surname><given-names>S</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name></person-group><article-title>Estimating the age of rare disease mutations: the example of Triple-A syndrome.</article-title><source>J Med Genet</source><year>2004</year><volume>41</volume><fpage>445</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15173230</pub-id></citation></ref><ref id="r25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hageman</surname><given-names>GS</given-names></name><name><surname>Anderson</surname><given-names>DH</given-names></name><name><surname>Johnson</surname><given-names>LV</given-names></name><name><surname>Hancox</surname><given-names>LS</given-names></name><name><surname>Taiber</surname><given-names>AJ</given-names></name><name><surname>Hardisty</surname><given-names>LI</given-names></name><name><surname>Hageman</surname><given-names>JL</given-names></name><name><surname>Stockman</surname><given-names>HA</given-names></name><name><surname>Borchardt</surname><given-names>JD</given-names></name><name><surname>Gehrs</surname><given-names>KM</given-names></name><name><surname>Smith</surname><given-names>RJ</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Russell</surname><given-names>SR</given-names></name><name><surname>Klaver</surname><given-names>CC</given-names></name><name><surname>Barbazetto</surname><given-names>I</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>Yannuzzi</surname><given-names>LA</given-names></name><name><surname>Barile</surname><given-names>GR</given-names></name><name><surname>Merriam</surname><given-names>JC</given-names></name><name><surname>Smith</surname><given-names>RT</given-names></name><name><surname>Olsh</surname><given-names>AK</given-names></name><name><surname>Bergeron</surname><given-names>J</given-names></name><name><surname>Zernant</surname><given-names>J</given-names></name><name><surname>Merriam</surname><given-names>JE</given-names></name><name><surname>Gold</surname><given-names>B</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Allikmets</surname><given-names>R</given-names></name></person-group><article-title>A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>7227</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15870199</pub-id></citation></ref><ref id="r26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Sekine</surname><given-names>A</given-names></name><name><surname>Ohnishi</surname><given-names>Y</given-names></name><name><surname>Johnson</surname><given-names>TA</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name></person-group><article-title>Linkage disequilibrium of evolutionarily conserved regions in the human genome.</article-title><source>BMC Genomics</source><year>2006</year><volume>7</volume><fpage>326</fpage><pub-id pub-id-type="pmid">17192199</pub-id></citation></ref></ref-list></back></article> 